Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia

Key facts

Sponsor

Children's Oncology Group

Principal Investigator

Paul S. Gaynon, MD, PA-C

Children's Hospital Los Angeles

Intervention

asparaginase(drug)

Enrollment

6 enrolled

Eligibility

1 years · All sexes

Timeline

2002 – 2006

Study locations (30)

• Phoenix Children's Hospital, Phoenix, Arizona, United States
• Loma Linda University Medical Center, Loma Linda, California, United States
• Children's Hospital Los Angeles, Los Angeles, California, United States
• Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
• Children's Hospital Central California, Madera, California, United States
• Children's Hospital of Oakland, Oakland, California, United States
• Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center, Orange, California, United States
• Children's Hospital of Orange County, Orange, California, United States
• Children's Hospital of Denver, Denver, Colorado, United States
• University of Connecticut Health Center, Farmington, Connecticut, United States
• Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States
• Children's National Medical Center, Washington D.C., District of Columbia, United States
• Emory University Hospital - Atlanta, Atlanta, Georgia, United States
• Children's Healthcare of Atlanta - Scottish Rite, Atlanta, Georgia, United States
• University of Chicago Cancer Research Center, Chicago, Illinois, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06326008
  Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
  Beijing GoBroad Hospital
• RECRUITINGPHASE2NCT06859424
  A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
  Center for International Blood and Marrow Transplant Research
• RECRUITINGPHASE2, PHASE3NCT06860269
  A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
  Assistance Publique - Hôpitaux de Paris
• RECRUITINGNCT06895538
  Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy
  Peking University First Hospital
• RECRUITINGNANCT06960993
  Mosaic Trial for Stem Cell Transplant Recipients
  Northwestern University
• RECRUITINGPHASE2NCT06816134
  Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
  The First Affiliated Hospital of Soochow University
• RECRUITINGPHASE2NCT06608732
  Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
  Institute of Hematology & Blood Diseases Hospital, China
• ACTIVE NOT RECRUITINGNANCT05968963
  Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
  University of Miami

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement →